News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Atox Bio Announces Dosing of the First Subject in Its Phase 1 Study of AB103



9/14/2010 12:30:20 PM

REHOVOT, Israel--(BUSINESS WIRE)--Atox Bio Inc. today announced that it successfully completed the dosing of the first subject in its phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.

Read at BioSpace.com


comments powered by Disqus
Atox Bio
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES